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We conducted surveillance for multidrug-resistant Plas-
modium falciparum in Cambodia during 2004–2006 by as-
sessing molecular changes in pfmdr1. The high prevalence 
of isolates with multiple pfmdr1 copies found in western 
Cambodia near the Thai border, where artesunate–meﬂ  o-
quine therapy failures occur, contrasts with isolates from 
eastern Cambodia, where this combination therapy remains 
highly effective.
T
he Thailand–Cambodia border has been an epicenter 
for drug-resistant Plasmodium falciparum. Recent 
clinical studies indicate that efﬁ  cacy of artesunate–meﬂ  o-
quine combination is decreasing on both sides of the bor-
der (1–3). In contrast, P. falciparum in eastern Cambodia 
remains sensitive to meﬂ  oquine and the artesunate–meﬂ  o-
quine combination (4,5). Declining artesunate–meﬂ  oquine 
efﬁ  cacy on the Thai border and the geographic variation in 
susceptibility to this combination therapy suggest expanded 
surveillance is needed in Cambodia. An inexpensive meth-
od to help target in vivo monitoring sites is surveillance for 
molecular markers of drug resistance. 
We have previously shown that elevated P. falciparum 
multidrug resistance 1 (pfmdr1) gene copy number is asso-
ciated with an 8-fold risk for artesunate–meﬂ  oquine failure 
in western Cambodia (6). More recently, we conducted a 
molecular surveillance for pfmdr1 mutations to guide the 
selection of sentinel sites for in vivo monitoring of artesu-
nate–meﬂ  oquine resistance.
The Study
Clinical isolates of P. falciparum were collected from 
5 sites across Cambodia (Figure 1): Pailin, Kampong Seila, 
Chumkiri (western), Memut, and Rattanakiri (eastern) dur-
ing 2004–2006. Study participants included patients who 
were seen at health centers with uncomplicated falcipar-
um malaria, including mixed infections. Fifty-six samples 
from patients in Pailin had been previously analyzed (6). 
Institutional review board approvals were obtained from 
the Cambodian National Ethics Committee for Health Re-
search, the US Naval Medical Research Unit No. 2, and the 
University of North Carolina at Chapel Hill (UNC).
Peripheral blood was used to prepare smears and ﬁ  lter 
paper blood spots (25 μL, 2 spots) on Whatman 3-mm blot-
ting paper (Whatman International Ltd., Maidstone, Kent, 
UK) from each participant. Blood smears were examined 
to determine parasite density, nonfalciparum species, and 
gametocytes. Enrolled participants completed a question-
naire on demographic information and past medical his-
tory. They received artesunate–meﬂ  oquine in accordance 
with national guidelines for uncomplicated falciparum ma-
laria. DNA was extracted from blood spots by using QI-
Amp Mini kits (QIAGEN, Valencia, CA, USA). pfmdr1 
copy number and single-nucleotide polymorphism assays 
were performed as previously described (6,7), except that 
in pfmdr1 single-nucleotide polymorphism assays the con-
centration of probes was reduced from 250 nM to 125 nM 
and reactions were not duplicated.
Linear regression was used to determine if pfmdr1 
copy number varied by site. pfmdr1 copy number was in-
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Figure 1. Map of Cambodia with locations of surveillance sites and 
proportion of isolates containing 1, 2, or >3 copies of pfmdr1, May 
2004–December 2006. Kg., Kampong.
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3verse transformed to meet assumptions of normality and 
homoscedasticity. Backwards elimination based on a p 
value of 0.05 was used to determine the effect of site when 
controlling for confounders. Logistical regression was used 
to conﬁ  rm the results of the linear regression analysis by 
using a cutoff of 1.5 copies (8). Logistic regression was 
also used to determine if pfmdr1-184 genotype varied by 
site. Samples with a mixture of 184-phe and 184-tyr were 
coded as 184-phe. All statistical analyses were conducted 
in Stata 8.2 (StataCorp, College Station, TX, USA).
We enrolled 744 study participants with uncompli-
cated P. falciparum malaria. The characteristics of partici-
pants at each site are described in Table 1. pfmdr1 copy 
number was successfully determined for 712 (95.7%) of 
744 samples. When compared with results at UNC, results 
of copy number assays performed by the National Malaria 
Control Program (NMCP) staff in Phnom Penh were slight-
ly lower (mean difference –0.163, 95% conﬁ  dence interval 
[CI] –0.277 to –0.049, n = 44), and the 2 groups were in 
100% concordance with distinguishing samples with >2 
pfmdr1 copies.
pfmdr1 copy numbers ranged from 0.6 to 6.3, and 167 
(23.5%) of 712 samples had >1.5 copies. The median and 
distribution of pfmdr1 copy number varied by site and were 
highest in the 3 western Cambodian sites (Figure 2). The 
proportion of samples with >1.5 pfmdr1 copies was greater 
in western than eastern Cambodia (52.7% vs. 6.4%, odds 
ratio [OR] = 16.2, 95% CI 10.3–25.3). The prevalence of 
parasite samples with ampliﬁ  ed pfmdr1 varied by site and 
differed in the prevalence of 2 and >3 copies of pfmdr1 
(Figure 1).
The prevalence of pfmdr1-184-Phe varied by site, was 
signiﬁ  cantly higher in the West (85.5% vs. 17.1%, OR = 
27.4, 95% CI 18.1–41.4), but was not more prevalent in 
samples with pfmdr1 copy number >1.5 when site was con-
trolled for (OR = 1.5, 95% CI 0.9–28, p = 0.139). pfmdr1 
codons 86, 1034, and 1042 were predominantly wild-type, 
356 (98.6%) of 361, 215 (97.7%) of 220, 347 (95.9%) of 
362, respectively, with little variation between sites (data 
not shown). Most (196 [91.2%] of 215) samples had the 
haplotypes 86-Asn, 1034-Ser, and 1042-Asn.
In univariate and multivariate linear regression mod-
els, site was the strongest predictor of pfmdr1 copy number. 
Chumkiri had the highest pfmdr1 copy number before and 
after clinical correlates were controlled for (Table 2). The 
relationship between copy number and site was retained 
when the analysis was repeated with logistic regression. 
Compared with Rattanakiri, the OR of having a copy num-
ber >1.5 was 32.4 (95% CI 16.4–64.2) for Chumkiri, 7.8 
(95% CI 4.3–13.9) for Pailin, and 0.5 (95% CI 0.2–1.2) for 
Memut when parasitemia and year were controlled for.
Conclusions
We found geographic heterogeneity for 2 pfmdr1 
genetic markers: pfmdr1 184 and pfmdr1 ampliﬁ  cation. 
Genotype 184-Phe was associated with pfmdr1 ampliﬁ  ca-
tion at the population level but not in individual isolates. 
The basis of this trend is unknown. Pailin, Kampong Seila, 
and Chumkiri in western Cambodia had higher pfmdr1 
copy numbers and higher prevalence of pfmdr1 184-Phe 
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Table 1. Clinical characteristics of study participants at 5 surveillance sites, Cambodia, May 2004–December 2006* 
Characteristic Pailin Kg. Seila† Chumkiri Memut Rattanakiri
Total no. 146 11 116 172 299
Male, no. (%)  98 (67.1)  9 (81.8)  97 (83.6)  62 (36.1)  187 (62.5) 
Adult (>18 y), no. (%)  128 (87.7)  11 (100.0)  109 (94.0)  172 (100.0)  221 (73.9) 
Parasitemia,‡ geometric mean  15,001 5,975 13,503 19,800 22,443
Parasitemia >50,000, no. (%)  47 (32.2)  4 (36.4)  33 (28.7)  68 (39.8)  120 (40.4) 
Gametocytemia, no. (%)  8 (5.5)  1 (9.0)  11 (9.6)  12 (7.0)  8 (2.7) 
Smear-positive malaria in past y, no.  (%)  35 (39.3)  2 (20.0)  25 (61.0)  13 (7.6)  127 (46.7) 
Antimalarial drug taken in past mo, no.  (%)  13 (14.4)  2 (18.2)  20 (17.2)  64 (37.2)  6 (2.0) 
Mixed infection, no.  (%)  6 (4.1)  1 (9.1)  8 (7.0)  3 (1.8)  6 (2.0) 
No. d of illness, median (range)  3 (1–6) 4 (2–6)  6 (1–6)  4 (2–6)  4 (0–6) 
*The missing values by category include parasitemia (n = 4), gametocytemia (n = 4), smear-positive malaria in past year (n = 160), antimalarial drug taken 
in past month (n = 56), mixed infection (n = 4), and no. of d of illness (n = 21). 
†Baseline differences were most likely due to small sample size. 
‡Parasites/PL.
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Figure 2. Median values and interquartile ranges of pfmdr1 copy 
number across 5 surveillance sites in Cambodia, May 2004–
December 2006. Kg., Kampong.Multidrug-Resistant P. falciparum, Cambodia
than Memut and Rattanakiri in eastern Cambodia. An asso-
ciation between these markers and resistance is consistent 
with reports of reduced efﬁ  cacy of artesunate–meﬂ  oquine 
in Pailin (79% over 42 days) (2) compared with Memut and 
Rattanakiri, where artesunate–meﬂ  oquine efﬁ  cacy remains 
close to 100% (4,5). This ﬁ  nding is also consistent with 
the decrease of meﬂ  oquine sensitivity in western Cambodia 
based on in vitro drug susceptibility monitoring conducted 
by the Pasteur Institute of Cambodia from 2001 through 
2007 (9,10; P. Lim, pers. comm.).
Chumkiri was surveyed because local health staff 
observed that falciparum malaria patients treated with 
artesunate–meﬂ  oquine often returned within weeks with 
recurrent fever and parasitemia. The possibility of such 
resistance in this site was particularly alarming because 
it was thought to be conﬁ  ned to Thailand–Cambodia bor-
der areas. Chumkiri had not previously been a sentinel site 
for antimalarial efﬁ  cacy monitoring by NMCP. On the 
basis of these pfmdr1 data, a clinical trial of artesunate–
meﬂ  oquine was launched in Chumkiri in 2006 (11). Clini-
cal validation of predicted resistance by in vivo studies is 
beyond the scope of this study, although multiple in vitro 
and in vivo studies have consistently shown an association 
of increased pfmdr1 copy number with meﬂ  oquine or arte-
sunate–meﬂ  oquine failure in Southeast Asia (8,10,12–15), 
supporting use of pfmdr1 copy number in routine surveil-
lance and policy formation.
Monitoring changes in antimalarial drug efﬁ  cacies is 
essential for guiding treatment policies in an era of mul-
tidrug resistance. However, such studies are resource in-
tensive. In Cambodia, for example, NMCP can conduct in 
vivo studies at only 2–3 sites per year because of limited 
funds and trained staff. Molecular markers can help tar-
get in vivo studies where they are most needed. Molecular 
surveillance is high-throughput and can be performed in a 
central laboratory on dried blood spots. Expanded surveil-
lance allows for molecular mapping and enables a rapid 
containment of resistance foci. pfmdr1 assays are now rou-
tinely performed in Cambodia by NMCP staff. National 
and regional molecular surveillance by malaria-endemic 
countries is a real possibility.
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